stoxline Quote Chart Rank Option Currency Glossary
PTC Therapeutics, Inc. (PTCT)
32.46  -0.35 (-1.07%)    07-19 14:28
Open: 32.98
High: 33.62
Volume: 280,431
Pre. Close: 32.81
Low: 32.44
Market Cap: 2,490(M)
Technical analysis
2024-07-19 1:52:48 PM
Short term     
Mid term     
Targets 6-month :  40.33 1-year :  44.52
Resists First :  34.52 Second :  38.11
Pivot price 32.17
Supports First :  28.71 Second :  23.89
MAs MA(5) :  33.39 MA(20) :  32.98
MA(100) :  31.79 MA(250) :  29.68
MACD MACD :  -0.4 Signal :  -0.6
%K %D K(14,3) :  65.1 D(3) :  63.5
RSI RSI(14): 46.1
52-week High :  42.13 Low :  17.53
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ PTCT ] has closed below upper band by 39.4%. Bollinger Bands are 30.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 34.22 - 34.4 34.4 - 34.55
Low: 31.94 - 32.13 32.13 - 32.3
Close: 32.48 - 32.82 32.82 - 33.11
Company Description

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Headline News

Fri, 19 Jul 2024
Inspire Investing LLC Sells 1,833 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - Defense World

Fri, 19 Jul 2024
PTC Therapeutics, Inc. (NASDAQ:PTCT) CFO Pierre Gravier Sells 2,269 Shares - Defense World

Thu, 18 Jul 2024
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Boosts Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Thu, 18 Jul 2024
Headlands Technologies LLC Sells 1,075 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - Defense World

Wed, 17 Jul 2024
Empowered Funds LLC Invests $1.21 Million in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Wed, 17 Jul 2024
41,598 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Bought by Empowered Funds LLC - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 77 (M)
Shares Float 57 (M)
Held by Insiders 2.3 (%)
Held by Institutions 113.5 (%)
Shares Short 7,350 (K)
Shares Short P.Month 8,920 (K)
Stock Financials
EPS -7.7
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -11.66
Profit Margin -62.5 %
Operating Margin -21.7 %
Return on Assets (ttm) -10.3 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth -4.7 %
Gross Profit (p.s.) 0
Sales Per Share 12.09
EBITDA (p.s.) -0.4
Qtrly Earnings Growth 0 %
Operating Cash Flow -58 (M)
Levered Free Cash Flow 8 (M)
Stock Valuations
PE Ratio -4.26
PEG Ratio 0.6
Price to Book value -2.81
Price to Sales 2.7
Price to Cash Flow -43.11
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android